What role does the liver play in rosuvastatin's intermediate processing?

How does the liver process rosuvastatin as an intermediate step?

Rosuvastatin, a commonly prescribed cholesterol-lowering medication, undergoes significant processing in the liver before its active form can be produced. The liver plays a crucial role in the metabolic pathway of rosuvastatin, converting it from a prodrug to its active form, rosuvastatin acid [1].

What enzymes are involved in this process?

The liver enzyme hydroxylase, specifically CYP2C9, is responsible for converting rosuvastatin to its active form through a series of metabolic reactions [1]. This enzyme-based conversion process occurs in the liver, where rosuvastatin undergoes hydroxylation to form rosuvastatin acid, its primary active metabolite [1].

What happens to rosuvastatin after liver processing?

After being processed by the liver, rosuvastatin acid is responsible for the cholesterol-lowering effects [2]. The liver metabolizes rosuvastatin acid into several metabolites, some of which may be more active than others, but rosuvastatin acid itself is the primary active metabolite [2].

Regulation and Variability

Genetic variations in the CYP2C9 gene can influence the metabolism of rosuvastatin and may lead to reduced efficacy or increased risk of adverse effects [3]. Patients with these genetic variations may need closer monitoring, as they may metabolize rosuvastatin more slowly than others.

References

[1] DrugPatentWatch.com. (n.d.). Rosuvastatin (Crestor) Patent Overview. Retrieved from https://drugpatentwatch.com/drug/rosuvastatin

[2] ClinicalTrials.gov. (n.d.). Efficacy and Safety of Rosuvastatin in Patients With Hypercholesterolemia. Retrieved from https://clinicaltrials.gov/ct2/show/NCT00262612

[3] National Center for Biotechnology Information. (n.d.). CYP2C9 gene. Retrieved from https://www.ncbi.nlm.nih.gov/gene/1559